<SEC-DOCUMENT>0000899140-22-000563.txt : 20220616
<SEC-HEADER>0000899140-22-000563.hdr.sgml : 20220616
<ACCEPTANCE-DATETIME>20220615211331
ACCESSION NUMBER:		0000899140-22-000563
CONFORMED SUBMISSION TYPE:	SC 13D/A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20220616
DATE AS OF CHANGE:		20220615
GROUP MEMBERS:		ALEXANDER J. DENNER, PH.D.

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMARIN CORP PLC\UK
		CENTRAL INDEX KEY:			0000897448
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SC 13D/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-52399
		FILM NUMBER:		221019224

	BUSINESS ADDRESS:	
		STREET 1:		SPACES SOUTH DOCKLANDS, BLOCK C
		STREET 2:		77 SIR JOHN ROGERSON'S QUAY
		CITY:			DUBLIN 2
		STATE:			L2
		ZIP:			D02 VK60
		BUSINESS PHONE:		353 1 6699 020

	MAIL ADDRESS:	
		STREET 1:		SPACES SOUTH DOCKLANDS, BLOCK C
		STREET 2:		77 SIR JOHN ROGERSON'S QUAY
		CITY:			DUBLIN 2
		STATE:			L2
		ZIP:			D02 VK60

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMARIN PHARMACEUTICALS PLC
		DATE OF NAME CHANGE:	20000201

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ETHICAL HOLDINGS PLC
		DATE OF NAME CHANGE:	19930322

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sarissa Capital Management LP
		CENTRAL INDEX KEY:			0001577524
		IRS NUMBER:				900924432
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SC 13D/A

	BUSINESS ADDRESS:	
		STREET 1:		660 STEAMBOAT ROAD
		CITY:			GREENWICH
		STATE:			CT
		ZIP:			06830
		BUSINESS PHONE:		203-302-2330

	MAIL ADDRESS:	
		STREET 1:		660 STEAMBOAT ROAD
		CITY:			GREENWICH
		STATE:			CT
		ZIP:			06830
</SEC-HEADER>
<DOCUMENT>
<TYPE>SC 13D/A
<SEQUENCE>1
<FILENAME>s53826129a.htm
<DESCRIPTION>SCHEDULE 13D/A, AMENDMENT #2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: asdf
         Document created using EDGARfilings PROfile 8.1.0.0
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="text-align: center; margin-bottom: 12pt; font-size: 12pt;"><font style="font-weight: bold;">UNITED STATES</font><br>
      <font style="font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</font><br>
      Washington, D.C. 20549</div>
    <div style="text-align: center; font-size: 14pt; font-weight: bold;">SCHEDULE 13D</div>
    <div><br>
    </div>
    <div style="text-align: center; font-size: 12pt;">Under the Securities Exchange Act of 1934</div>
    <div style="text-align: center;"><font style="font-size: 12pt;">(Amendment No. 2)*<br>
      </font><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="zf3ff62f656984aec9714cea6a7c733f8" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 100%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-size: 12pt;">Amarin Corporation plc</div>
          </td>
        </tr>
        <tr>
          <td style="width: 100%; vertical-align: top; border-top: #000000 2px solid;">
            <div style="text-align: center;">(Name of Issuer)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 100%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 100%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-size: 12pt;">Ordinary Shares, par value 50 pence per share</div>
          </td>
        </tr>
        <tr>
          <td style="width: 100%; vertical-align: top; border-top: #000000 2px solid;">
            <div style="text-align: center;">(Title of Class of Securities)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 100%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 100%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-size: 12pt;">023111206</div>
          </td>
        </tr>
        <tr>
          <td style="width: 100%; vertical-align: top; border-top: #000000 2px solid;">
            <div style="text-align: center;">(CUSIP Number)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 100%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 100%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-size: 12pt;">Mark DiPaolo</div>
            <div style="text-align: center; font-size: 12pt;">Senior Partner, General Counsel</div>
            <div style="text-align: center; font-size: 12pt;">Sarissa Capital Management LP</div>
            <div style="text-align: center; font-size: 12pt;">660 Steamboat Road</div>
            <div style="text-align: center; font-size: 12pt;">Greenwich, CT 06830</div>
            <div style="text-align: center; font-size: 12pt;">203-302-2330</div>
          </td>
        </tr>
        <tr>
          <td style="width: 100%; vertical-align: top; border-top: #000000 2px solid;">
            <div style="text-align: center;">(Name, Address and Telephone Number of Person<br>
              Authorized to Receive Notices and Communications)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 100%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 100%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-size: 12pt;">June 15, 2022</div>
          </td>
        </tr>
        <tr>
          <td style="width: 100%; vertical-align: top; border-top: #000000 2px solid;">
            <div style="text-align: center;">(Date of Event which Requires Filing of this Statement)</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: justify; margin-bottom: 12pt;">If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e),
      13d-1(f) or 13d-1(g), check the following box. &#9744;</div>
    <div style="text-align: justify; margin-bottom: 12pt;"><font style="font-weight: bold;">Note:</font>&#160; Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other
      parties to whom copies are to be sent.</div>
    <div>*The remainder of this cover page shall be filled out for a reporting person&#8217;s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures
      provided in a prior cover page.</div>
    <div><br>
    </div>
    <div style="text-align: justify;">The information required on the remainder of this cover page shall not be deemed to be &#8220;filed&#8221; for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that
      section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).</div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div> </div>
    <br>
    <div style="text-align: justify;">
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zafd0525d5836421ab23e6516493a2610">

          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div>CUSIP No. <font style="font-family: 'Times New Roman',Times,serif;">023111206</font></div>
            </td>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: right;">Page 2 of 3 Pages</div>
            </td>
          </tr>

      </table>
    </div>
    <div style="text-align: justify;"> <br>
    </div>
    <div style="text-align: center;">SCHEDULE 13D </div>
    <div style="text-align: justify;"> <br>
    </div>
    <div style="text-align: justify;"> <br>
    </div>
    <div style="text-align: justify;">This Amendment No. 2 to Schedule 13D (&#8220;Amendment No. 2&#8221;) relates to American Depositary Shares (&#8220;ADS(s)&#8221;), each ADS representing one ordinary share, par value 50 pence per share (the &#8220;Ordinary Shares&#8221;), issued by
      Amarin Corporation plc, a company incorporated under the laws of England and Wales (the &#8220;Issuer&#8221;), and amends the initial statement on Schedule 13D filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on January 24, 2022 (the &#8220;Initial
      Schedule 13D&#8221;) as amended by Amendment No. 1 to Schedule 13D filed on June 3, 2022 (&#8220;Amendment No. 1&#8221; and together with the Initial Schedule 13D, the &#8220;Schedule 13D&#8221;) on behalf of the Reporting Persons, to furnish the additional information set forth
      herein. All capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Schedule 13D.</div>
    <div style="margin-top: 6pt; margin-bottom: 6pt;"><font style="font-weight: bold;">Item 4. Purpose of Transaction. </font>Item 4 of the Schedule 13D is hereby amended to include the following:</div>
    <div style="text-align: justify; margin-top: 6pt; margin-bottom: 6pt;">On June 15, 2022,&#160;Sarissa Capital&#160;issued&#160;a press release&#160;indicating how the Reporting Persons intend to vote at the upcoming annual meeting of the Issuer and the reasons therefor. A
      copy of the press release is attached as Exhibit 2 hereto.</div>
    <div style="text-align: justify;"><font style="font-weight: bold;">Item 7. Material to Be Filed as Exhibits. </font>Item 7 of the Schedule 13D is hereby amended to include the following:</div>
    <div><br>
    </div>
    <div style="text-align: justify;">Exhibit 2 &#8211; Press Release, June 15, 2022</div>
    <div><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="margin-bottom: 18pt; font-weight: bold;">
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zafd0525d5836421ab23e6516493a2610">

          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div>CUSIP No. <font style="font-family: 'Times New Roman',Times,serif;">023111206</font></div>
            </td>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: right;">Page 3 of 3 Pages</div>
            </td>
          </tr>

      </table>
      <div style="text-align: center; font-weight: normal;">SCHEDULE 13D</div>
    </div>
    <div style="text-align: center; margin-bottom: 18pt; font-weight: bold;"><br>
      SIGNATURE</div>
    <div style="text-align: justify; text-indent: 36pt;">After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.</div>
    <div><br>
    </div>
    <div>Dated: June 15, 2022</div>
    <div><br>
    </div>
    <div>SARISSA CAPITAL MANAGEMENT LP</div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div>By:<font id="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt">&#160;</font><u>/s/ Mark DiPaolo </u>_______________________<br>
      <font id="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt">&#160;</font>Name: Mark DiPaolo<br>
      <font id="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt">&#160;</font>Title: Senior Partner, General Counsel</div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><u>/s/ Alexander J. Denner</u>________________________<br>
      Alexander J. Denner</div>
    <div><br>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2
<SEQUENCE>2
<FILENAME>53826129b.htm
<DESCRIPTION>PRESS RELEASE JUNE 15, 2022
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: asdf
         Document created using EDGARfilings PROfile 8.1.0.0
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div><br>
  </div>
  <div>
    <div style="text-align: right;">EXHIBIT 2</div>
    <div><br>
    </div>
    <div style="text-align: center; font-style: italic;">SARISSA CAPITAL INTENDS TO VOTE &#8220;ABSTAIN&#8221; AT THE AMARIN ANNUAL MEETING</div>
    <div><br>
    </div>
    <div style="text-align: center; font-style: italic;">Sarissa intends to &#8220;Abstain&#8221; given ongoing engagement with Amarin to add shareholder representatives to the board</div>
    <div><br>
    </div>
    <div>Greenwich, CT, June 15, 2022 &#8211; Sarissa Capital Management LP (&#8220;Sarissa&#8221;) today made the following statement on Amarin Corporation plc (NASDAQ: AMRN) regarding how it intends to vote at the upcoming Amarin annual meeting and the reasons therefor:</div>
    <div><br>
    </div>
    <div>Sarissa is a sophisticated, institutional investor with a long history of shareholder value creation in healthcare companies, including in the cardiovascular space, such as The Medicines Company. As Amarin&#8217;s largest shareholder, we are frustrated
      by the performance of Amarin&#8217;s stock and believe Amarin should be better managed to maximize value for shareholders.</div>
    <div><br>
    </div>
    <div>Sarissa has discussed with the company our desire to add directors to the board. Although we are hopeful that the board will see the value that Sarissa brings as the largest shareholder and with a track record of creating shareholder value for
      cardiovascular disease focused companies, we are uncertain how our discussions regarding board representation will proceed. We note that despite a board refreshment process that began last October, the independent directors never proactively
      contacted Sarissa despite us being Amarin&#8217;s largest shareholder with a strong track record of value creation in cardiovascular care, such as The Medicines Company.</div>
    <div><br>
    </div>
    <div>Many shareholders have reached out asking how we intend to vote at the upcoming annual meeting.</div>
    <div> <br>
    </div>
    <div>Given ongoing discussions, we intend to vote &#8220;ABSTAIN&#8221; on all matters at the annual meeting. We believe this reinforces our message that change is needed as we give the board the time to add shareholder representatives to the board.</div>
    <div><br>
    </div>
    <div>In addition, we intend to vote &#8220;ABSTAIN&#8221; at the annual meeting because even though such a vote will not impact the outcome of the upcoming election of directors, the United Kingdom, the jurisdiction in which Amarin is domiciled, contains laws and
      rights that protect the shareholder franchise even after the annual meeting. For example, under UK law and Amarin&#8217;s articles, shareholders, like Sarissa, who own at least 5% of the outstanding shares can call a special meeting of shareholders to
      remove and replace directors AT ANY TIME. Therefore, immediately after the annual meeting, we could call a special meeting and seek to remove and replace some or all of the Amarin directors with the affirmative vote of the holders of a majority of
      the outstanding shares.</div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z431c5194f5a6426f84c0be7467ef2393">

        <tr>
          <td style="width: 72pt; vertical-align: top; align: right;">Contact:</td>
          <td style="width: auto; vertical-align: top;">
            <div>Jean Puong<br>
              Sarissa Capital Management LP<br>
              info@sarissacap.com</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
